Dedicated to Conquering Heart Failure
A clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease
COVID-19 and CVD
Cardiol has been approved by the FDA for a Phase II/III clinical trial to test the efficacy of CardiolRx™ in improving outcomes for COVID-19 patients with cardiovascular disease (CVD).
Learn More
Acute Myocarditis
Cardiol is planning a Phase II international trial of acute myocarditis, the most common cause of sudden cardiac death in people under 35 years of age.
Learn More
Heart Failure
Committed to conquering a serious condition that affects more than 26 million people globally.
Learn More
LATEST NEWS
All News
Press Release
Cardiol Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference
September 16, 2021
Cardiol Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference
IN THE MEDIA
In an interview with Pharmacy Times®, Guillermo Torre-Amione, MD, PhD, FACC, the Chairman of Cardiol Therapeutics, discusses the potential use for cannabidiol (CBD) in hospitalized patients with COVID-19, as well as its therapeutic benefits in certain patients with cardiovascular disease.
In this discussion, Dr. Torre-Amione explains the potential benefits for anti-inflammatory therapies for these patients, as well as how CBD specifically can be applied. He also describes a use for CBD in treating cardiovascular disease related to viral damage, and what other anti-inflammatory therapies may soon be available.
TSX:CRDL NASDAQ:CRDL
